JP2005513026A5 - - Google Patents

Download PDF

Info

Publication number
JP2005513026A5
JP2005513026A5 JP2003545635A JP2003545635A JP2005513026A5 JP 2005513026 A5 JP2005513026 A5 JP 2005513026A5 JP 2003545635 A JP2003545635 A JP 2003545635A JP 2003545635 A JP2003545635 A JP 2003545635A JP 2005513026 A5 JP2005513026 A5 JP 2005513026A5
Authority
JP
Japan
Prior art keywords
substituted
compound
compound according
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/036583 external-priority patent/WO2003043998A1/en
Publication of JP2005513026A publication Critical patent/JP2005513026A/ja
Publication of JP2005513026A5 publication Critical patent/JP2005513026A5/ja
Pending legal-status Critical Current

Links

JP2003545635A 2001-11-15 2002-11-15 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環 Pending JP2005513026A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33479401P 2001-11-15 2001-11-15
US36273202P 2002-03-08 2002-03-08
US36270202P 2002-03-08 2002-03-08
PCT/US2002/036583 WO2003043998A1 (en) 2001-11-15 2002-11-15 N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases

Publications (2)

Publication Number Publication Date
JP2005513026A JP2005513026A (ja) 2005-05-12
JP2005513026A5 true JP2005513026A5 (https=) 2006-01-12

Family

ID=27407005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545635A Pending JP2005513026A (ja) 2001-11-15 2002-11-15 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環

Country Status (5)

Country Link
US (2) US7071218B2 (https=)
EP (1) EP1456187A4 (https=)
JP (1) JP2005513026A (https=)
AU (1) AU2002352706A1 (https=)
WO (1) WO2003043998A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517993A (en) 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
IL157740A0 (en) * 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
US7265139B2 (en) * 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
WO2003016267A1 (en) * 2001-08-17 2003-02-27 Incyte San Diego Incorporated Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
AU2003291024A1 (en) * 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
CN1774246A (zh) * 2003-04-18 2006-05-17 因齐特圣迭戈公司 用于治疗代谢失调、癌症和其它疾病的取代异色满化合物
EP1758651A2 (en) * 2004-06-24 2007-03-07 Galapagos N.V. Lxr agonists to promote bone homeostasis
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006041921A2 (en) * 2004-10-05 2006-04-20 Auspex Pharmaceuticals, Inc. Preparation and uses of rhodanine derivatives
JP4780372B2 (ja) * 2005-03-02 2011-09-28 独立行政法人産業技術総合研究所 キノキサリンジオン誘導体及びその製造方法並びにその用途
US7638533B2 (en) * 2005-09-30 2009-12-29 Janssen Pharmaceutica N.V. Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
CN101801187B (zh) * 2007-07-13 2014-07-23 得克萨斯系统大学评议会 大麻素受体的杂环调节剂
EP2217235A4 (en) * 2007-11-15 2011-01-12 Musc Found For Res Dev INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
ATE536347T1 (de) 2008-05-20 2011-12-15 Merck Sharp & Dohme Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
AU2009330686B2 (en) * 2008-06-16 2014-07-03 The Ohio State University Research Foundation Compounds for the treatment of cancer
HUP0800768A2 (en) 2008-12-18 2012-08-28 Bioblocks Magyarorszag Gyogyszerkemiai Es Fejlesztoe Kft 1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
US8530687B2 (en) 2010-09-07 2013-09-10 University Of Florida Research Foundation, Inc. Catalysts, methods of making catalysts, and methods of use
JP6014816B2 (ja) 2011-05-10 2016-10-26 国立大学法人神戸大学 Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体
WO2014082042A2 (en) 2012-11-25 2014-05-30 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
WO2015023827A1 (en) * 2013-08-14 2015-02-19 North Carolina Central University A high-throughput assay for identifying small molecules that modulate amp-activated protein kinase (ampk)
CN104447252A (zh) * 2013-09-18 2015-03-25 浙江天新药业有限公司 一种6-甲氧基-2-萘甲醛的制备方法
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US20170114019A1 (en) 2014-06-04 2017-04-27 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
KR102874295B1 (ko) 2017-02-17 2025-10-20 에이도스 테라퓨틱스, 인코포레이티드 Ag-10, 이의 중간체, 및 이의 염을 제조하는 방법
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
US11058668B2 (en) 2018-03-23 2021-07-13 Eidos Therapeutics, Inc. Methods of treating TTR amyloidosis using AG10
IL325404A (en) 2018-08-17 2026-02-01 Eidos Therapeutics Inc Spice formulations containing 3-(3-(5,3-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
US4713224A (en) * 1986-03-31 1987-12-15 The Boc Group, Inc. One-step process for purifying an inert gas
JP2539504B2 (ja) 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
IE62214B1 (en) 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
ATE173728T1 (de) 1991-07-22 1998-12-15 Pfizer Verfahren zur herstellung von (s)-4-(3-(5-methyl- 2-phenyl-4-oxazolyl)- 1-hydroxypropyl> brombenzol
DE10199033I2 (de) 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
JPH08506323A (ja) 1992-11-25 1996-07-09 ラ ホヤ キャンサー リサーチ ファウンデーション Ｒｘｒホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
AU692839B2 (en) 1994-02-17 1998-06-18 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
EP0850067A4 (en) 1995-07-17 1999-12-15 Cird Galderma METHODS OF TREATING CANCER USING 6- 3- 1-ADAMANTYL] -4-HYDROXYPHENYL]
EP0844997A1 (en) 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
IL127946A0 (en) 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
WO1999009965A2 (en) 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
JP4398585B2 (ja) 1997-11-12 2010-01-13 有限会社ケムフィズ レチノイドレセプター作用剤
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
ID27787A (id) * 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
WO2000032598A1 (en) 1998-12-04 2000-06-08 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
NZ517993A (en) * 1999-08-31 2004-03-26 Incyte San Diego Inc Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
KR100608416B1 (ko) 1999-11-12 2006-08-02 후지모토 쿄다이 가부시키가이샤 2-(ｎ-시아노이미노)티아졸리딘-4-온 유도체
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
IL157740A0 (en) * 2001-03-07 2004-03-28 Incyte San Diego Inc Heterocyclic derivatives and pharmaceutical compositions containing the same
US7265139B2 (en) 2001-03-08 2007-09-04 Incyte San Diego Inc. RXR activating molecules
EP1373240B1 (en) 2001-03-14 2005-06-15 Eli Lilly And Company Retinoid x receptor modulators
WO2002072099A1 (en) 2001-03-14 2002-09-19 Mitsubishi Pharma Corporation Therapeutic and/or preventive agent for diabetic ischemic heart disease
JP4590158B2 (ja) * 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
JP2006500399A (ja) * 2002-04-30 2006-01-05 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネルブロッカーとしての、アリール−結合−アリール置換された、チアゾリジン−ジオンおよびオキサゾリジン−ジオン

Similar Documents

Publication Publication Date Title
JP2005513026A5 (https=)
US10442782B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
RU2563639C2 (ru) Замещенные соединения амида
RU2419624C2 (ru) Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2
EP2383263B1 (en) Novel thiazolidinedione derivative and use thereof
CN102137592B (zh) 用于治疗癌症的化合物
JP5517935B2 (ja) 細胞壊死阻害剤としてのインドール及びインダゾール化合物
JP5597542B2 (ja) Ｓｃｄ阻害薬としてのトリアゾール誘導体
WO2018213150A1 (en) Usp30 inhibitors
TW200410671A (en) Medicines for inhibiting the activation of AP-1
CN1378541A (zh) c－JUN N－末端激酶(JNK)和其它蛋白激酶的抑制剂
WO2001074771A1 (en) Pyrrole-2,5-dione derivatives for the treatment of diabetes
KR20080040046A (ko) 티아졸 유도체
CN115697974A (zh) 基于咪唑3-氧化物衍生物的acss2抑制剂和其使用方法
JP2008513515A5 (https=)
US20240287098A1 (en) Compositions and methods for treating cancer
WO2015125842A1 (ja) トリアジン化合物及びその医薬用途
WO2008016175A1 (en) Activator for peroxisome proliferator activated receptor
WO2010137350A1 (ja) 神経栄養因子の活性が関与する疾患の治療または予防剤
CN112189012A (zh) 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物
JP2023123607A (ja) ベンゼン誘導体
RU2612533C2 (ru) Производные фенилгуанидина
CN102558167A (zh) Gk和ppar双重激动活性的噻唑烷二酮衍生物
CN110709393A (zh) Ldha活性抑制剂
KR20120047960A (ko) 글루코키나아제(ｇｋ) 활성화제로서 치환된 벤즈아미드 유도체